These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 2493412)

  • 1. [Thrombolysis following myocardial infarct: benefits are clarified].
    Michel D
    Fortschr Med; 1989 Jan; 107(3):14-5. PubMed ID: 2493412
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thrombolysis in myocardial infarction (TIMI) trial phase I and phase IIA pilot results. Implications for nursing.
    Brewer-Senerchia C
    Prog Cardiovasc Nurs; 1988; 3(4):128-36. PubMed ID: 2974593
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant tissue-type plasminogen activator in acute myocardial infarction: role of the critical care nurse.
    Kline EM
    Heart Lung; 1987 Nov; 16(6 Pt 2):779-86. PubMed ID: 2960639
    [No Abstract]   [Full Text] [Related]  

  • 5. [Thrombolysis in acute myocardial infarct: prerequisites, current experiences and remaining problems].
    Rapold HJ
    Schweiz Med Wochenschr; 1986 Aug; 116(33):1074-87. PubMed ID: 3094141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic fibrinolysis with recombinant tissue-type plasminogen activator in subrenal aortic occlusions].
    Hönigl K; Pilger E; Stark G; Bertuch H
    Vasa Suppl; 1988; 26():99-102. PubMed ID: 3144050
    [No Abstract]   [Full Text] [Related]  

  • 7. [Thrombolysis in acute myocardial infarct].
    Görge G; Erbel R
    Dtsch Med Wochenschr; 1994 May; 119(19):717. PubMed ID: 8187628
    [No Abstract]   [Full Text] [Related]  

  • 8. [Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct].
    Bleifeld W; Verstraete M; Brower RW; Collen D; Dunning AJ; Lubsen J; Michel PL; Schofer J; Vanhaecke J; Van de Werf F
    Klin Wochenschr; 1988; 66 Suppl 12():86-92. PubMed ID: 3126349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The value of late thrombolytic perfusion in acute myocardial infarct].
    Gulba DC
    Z Kardiol; 1993; 82 Suppl 2():183-5. PubMed ID: 8328200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the thrombolysis and angioplasty in acute myocardial infarction (TAMI) trials.
    Topol EJ
    Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():45-9. PubMed ID: 2973302
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [rt-PA in acute myocardial infarct, randomized studies in Europe and the USA].
    von Essen R
    Z Kardiol; 1986; 75 Suppl 5():101-6. PubMed ID: 3103344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
    Negrini M
    G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombolysis, streptokinase, and TPA in the treatment of acute myocardial infarction.
    Mock MB; Chesebro JH
    Cardiovasc Clin; 1987; 18(1):247-57. PubMed ID: 2955892
    [No Abstract]   [Full Text] [Related]  

  • 15. [Thrombolysis in acute myocardial infarct. Initial experiences in a Swiss university hospital].
    Ritz R; Schoenenberger R; Burckhardt D; Burkart F; Pfisterer M; Ritschard T; Weiss P
    Schweiz Med Wochenschr; 1988 Nov; 118(46):1706-10. PubMed ID: 3145557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
    Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
    Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study on the effects of low dose of tPA and different regimens of intravenous urokinase in acute myocardial infarction.
    Shen W; Zhang R; Zhang J; Zhang D; Zhang X; Zheng A
    Chin Med J (Engl); 1999 Jan; 112(1):18-21. PubMed ID: 11593632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant tissue-type plasminogen activator as a thrombolytic agent in acute myocardial infarction.
    Parr KL; Valentine RP; Pitts DE; Schumacher RR; Schmidt PE; Brooks-Brunn JA; Ramsden C
    Indiana Med; 1987 May; 80(5):460-1. PubMed ID: 2953781
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of metabolic syndrome on coronary patency after thrombolytic therapy for acute myocardial infarction.
    Yasar AS; Bilen E; Bilge M; Arslantas U; Karakas F
    Coron Artery Dis; 2009 Sep; 20(6):387-91. PubMed ID: 19696662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.